Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given an average rating of “Hold” by the seven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $8.67.

Several brokerages recently issued reports on SGMO. BidaskClub downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 28th. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Wedbush reiterated a “neutral” rating and set a $4.00 price target (down previously from $6.00) on shares of Sangamo Therapeutics in a report on Tuesday, May 16th. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $17.00 price target on shares of Sangamo Therapeutics in a report on Thursday, June 22nd.

Sangamo Therapeutics (NASDAQ SGMO) traded up 0.862% during midday trading on Tuesday, hitting $8.775. The stock had a trading volume of 294,639 shares. The stock’s market capitalization is $631.26 million. The stock’s 50-day moving average is $8.85 and its 200-day moving average is $5.93. Sangamo Therapeutics has a 1-year low of $2.65 and a 1-year high of $10.50.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. The business had revenue of $3.40 million during the quarter, compared to the consensus estimate of $4.14 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Sangamo Therapeutics’s revenue was down 12.8% compared to the same quarter last year. On average, equities research analysts anticipate that Sangamo Therapeutics will post ($0.93) EPS for the current fiscal year.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the transaction, the vice president now owns 35,517 shares of the company’s stock, valued at $355,170. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 19,639 shares of company stock worth $184,765. Insiders own 8.10% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of SGMO. Candriam Luxembourg S.C.A. boosted its position in shares of Sangamo Therapeutics by 35.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 70,000 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in shares of Sangamo Therapeutics during the first quarter worth approximately $496,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Sangamo Therapeutics during the first quarter worth approximately $154,000. Wells Fargo & Company MN boosted its position in shares of Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 34,128 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares in the last quarter. 58.25% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of “Hold” by Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/sangamo-therapeutics-inc-nasdaqsgmo-given-average-rating-of-hold-by-analysts.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.